Evidence suggests that the European Society of Cardiology (ESC)/European Society of Hypertension (ESH) hypertension guidelines recommend initial dual therapy consisting of a beta‐blocker combined with a Renin–Angiotensin System (RAS) blocker or a dihydropyridine calcium channel blocker (CCB).37 This evidence concerns the gene REN and hypertensive disorder.